A Choobineh, E Solaymani, A Mohammad Beigi,
Volume 5, Issue 3 (20 2009)
Abstract
Background & Objectives: Work-related Musculoskeletal Disorders (WMSDs) seen more in workers of manufacturing industry than others. This study was, therefore, conducted to determine prevalence rate of WMSDs symptoms among workers of a metal manufacturing industry in Shiraz.
Methods: In this study, nearly 50% of workers of the production units were randomly selected from corresponding list of each unit. Totally, 156 workers participated in this study. A self-administrated questionnaire was used to collect required data. T-test and Chi-square tests were used to analyze the data.
Results: The results showed that WMSDs occurred in considerable rate among the workers such that 76.9% of the workers studied suffered from some kind of symptoms during the last 12 months. The highest prevalence was reported in the lower back (54.5%) and knees (42.9%). Machine operators and welders reported the highest rate of symptoms. Statistical analyses revealed significant association between age, height, work tenure, weekly work hours, smoking, shift work and the symptoms (P<0.05).
Conclusions: WMSDs symptoms occurrence was prevalent among workers of this industry. To prevent WMSDs symptoms, more attention should be paid to working conditions of the machine operators and the welders, and risk factors for back and knee regions should be reduced.
F Fakhri, S Eybpoosh, M Solaymani Dodaran ,
Volume 15, Issue 1 (Vol.15, No.1 2019)
Abstract
Background and Objectives: A considerable number of clinical trials are conducted in Iran each year. Not much is known about the characteristics of them, this study aimed to investigate key characteristics of Iranian clinical trials.
Methods: All clinical trial protocols registered in IRCT until November 2013 were selected. Text mining techniques were used to extract information from data that was mostly in the textual format. Stata software (v. 11) was used for both extraction and analysis.
Results: Totally 5049 trials where analyzed. Trials were in 40 different areas of medicine and their annual number was increasing. The sample size of registered trials was less than 70 in most trials and showed no significant improvement during the 5-year period (Median sample size= 64, inter quartile range (IQR) = 40-100). Phase III trials comprised 8.4% of the trials with a median sample size of 75 (IQR= 50-120). Of all phase III trials, 69% had a target sample size of less than 100. Most trials used randomization techniques (87.2%) but failed to use placebo (65.3%) and double/triple-blinding techniques (55.8%). The leading sponsors for 99.9% of trials were national bodies and 92.2% of the trials received public funds. Only 1% of the trials were exclusively sponsored by pharmaceutical companies.
Conclusion: The majority of clinical trials conducted in Iran are investigator-initiated and are funded by the public sector. The small sample size and failures in bias control observed in the majority of trials highlights the need for revising current policies of conducting trials in Iran.
